China

Aspen China was incorporated as a wholly foreign-owned enterprise in July 2015 but has not been a significant contributor to the Group performance prior to the 2017 financial year. China is set to become a material contributor to Group revenue with a product range comprising the recently acquired thrombosis and anaesthetic brands as well as some smaller global brands.

Contribution to Group revenue

Revenue contribution - by therapeutic category

China made up 37% of the total Asian pharmaceutical sector with an estimated value of USD80 billion as at 30 December 2016.
Over the same period, the China pharmaceutical sector grew 7,9% in local currency, mostly driven by the 8,4% growth in prescription medication usage in hospitals.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2016: n/a)

Number of product recalls:

Nil

(2016: n/a)

Number of work-related fatalities:

Nil

(2016: n/a)

Number of permanent employees:

Revenue – R’billion	2017	2016 (CER)*	% change
Total	1,8	–	>100
Anaesthetics	1,5	–	>100
Thrombosis	0,3	–	>100

* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.